Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al

Lea C. Berkhout; Merel J. l'ami; Gerrit Jan Wolbink; Theo Rispens

doi:https://doi.org/10.1136/annrheumdis-2019-216557

Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al

Lea C. Berkhout, Merel J. l'ami, Gerrit Jan Wolbink, Theo Rispens

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Original language	English
Article number	216557
Journal	Annals of the rheumatic diseases
DOIs	https://doi.org/10.1136/annrheumdis-2019-216557
Publication status	Published - 2019

Access to Document

https://doi.org/10.1136/annrheumdis-2019-216557

Cite this

Berkhout, L. C., l'ami, M. J., Wolbink, G. J., & Rispens, T. (2019). Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al. Annals of the rheumatic diseases, Article 216557. https://doi.org/10.1136/annrheumdis-2019-216557

@article{24e905f7ba304f978153e4db5d94ba1f,

title = "Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al",

author = "Berkhout, {Lea C.} and l'ami, {Merel J.} and Wolbink, {Gerrit Jan} and Theo Rispens",

year = "2019",

doi = "https://doi.org/10.1136/annrheumdis-2019-216557",

language = "English",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

}

Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al. / Berkhout, Lea C.; l'ami, Merel J.; Wolbink, Gerrit Jan et al.
In: Annals of the rheumatic diseases, 2019.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al

AU - Berkhout, Lea C.

AU - l'ami, Merel J.

AU - Wolbink, Gerrit Jan

AU - Rispens, Theo

PY - 2019

Y1 - 2019

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075349738&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31744825

U2 - https://doi.org/10.1136/annrheumdis-2019-216557

DO - https://doi.org/10.1136/annrheumdis-2019-216557

M3 - Comment/Letter to the editor

C2 - 31744825

SN - 0003-4967

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

M1 - 216557

ER -

Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al

Access to Document

Other files and links

Cite this